Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cartesian Therapeutics (RNAC) has issued an update.
At the 2024 Annual Meeting of Cartesian Therapeutics, Inc., stockholders ratified significant proposals, including the election of two Class II Directors, the approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the year. Additionally, they approved the Amended and Restated 2016 Incentive Award Plan, which aims to incentivize employees with awards linked to the company’s performance, enhancing their dedication to the company’s growth and success.
Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.